Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Ooki A, et al. Among authors: kataoka m. Cancer Med. 2020 Dec;9(24):9419-9430. doi: 10.1002/cam4.3564. Epub 2020 Nov 21. Cancer Med. 2020. PMID: 33222406 Free PMC article. Clinical Trial.
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K, Kobayashi M, Kojima H, Hirabayashi N, Kataoka M, Araki K, Matsui T, Takiyama W, Miyashita Y, Nakazato H, Nakao A, Sakamoto J. Kondo K, et al. Among authors: kataoka m. Jpn J Clin Oncol. 2005 Jun;35(6):332-7. doi: 10.1093/jjco/hyi096. Epub 2005 Jun 16. Jpn J Clin Oncol. 2005. PMID: 15961435 Clinical Trial.
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO and KCSG Study Group. Koizumi W, et al. J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. doi: 10.1007/s00432-013-1563-5. Epub 2013 Dec 24. J Cancer Res Clin Oncol. 2014. PMID: 24366758 Free PMC article. Clinical Trial.
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S, Kono T. Matsuda C, et al. Among authors: kataoka m. Cancer Chemother Pharmacol. 2015 Jul;76(1):97-103. doi: 10.1007/s00280-015-2767-y. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983022 Free PMC article. Clinical Trial.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Ann Surg Oncol. 2017. PMID: 27638675 Clinical Trial.
Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Ann Surg Oncol. 2016 Dec;23(Suppl 5):1064. doi: 10.1245/s10434-016-5593-5. Ann Surg Oncol. 2016. PMID: 27646021 No abstract available.
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial).
Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K. Kotake M, et al. Among authors: kataoka m. Oncol Lett. 2017 Feb;13(2):747-753. doi: 10.3892/ol.2016.5505. Epub 2016 Dec 14. Oncol Lett. 2017. PMID: 28356954 Free PMC article.
1,855 results